Trials / Recruiting
RecruitingNCT06514768
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Early Exploratory Clinical Study on the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Acute B Lymphoblastic Leukemia
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Academic / Other
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- Not accepted
Summary
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JY231 | Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units (TU)/kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required) |
Timeline
- Start date
- 2024-06-20
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2024-07-23
- Last updated
- 2026-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06514768. Inclusion in this directory is not an endorsement.